Kenneth Ray Hunter

US Patent:

50575988, Oct 15, 1991

Filed:

Feb 1, 1989

Appl. No.:

7/304884

Inventors:

Matthew Pollack - Bethesda MD
Kenneth W. Hunter - Kensington MD

Assignee:

Centocor, Inc. - Malvern PA

International Classification:

A61K 39395
C07K 1528
C12N 1205

US Classification:

530387

Abstract:

Novel monoclonal antibodies are disclosed, the production of which is specified by particular genes contained, conveniently, in biologically pure cultures of self-reproducing carrier cells, such as, but not limited to, ATCC HB 8297 and ATCC HB 8298, such antibodies being reactive with at least part of endotoxin core of Gram-negative bacteria. Processes of prepa U. S. GOVERNMENT RIGHTS The invention described herein may be manufactured, used and licensed by or for the U. S. Government for governmental purposes only without the payment to the inventors of any royalties thereon.

US Patent:

47449829, May 17, 1988

Filed:

Aug 24, 1982

Appl. No.:

6/411115

Inventors:

Kenneth W. Hunter - Kensington MD
Gerald W. Fischer - Gaithersburg MD

International Classification:

A61K 3940
C12N 1500
G01N 3353

US Classification:

424 87

Abstract:

A human monoclonal antibody produced by a self-reproducing carrier cell, the antibody being reactive with PRP capsular polysaccharide. Also disclosed is a process of preparing the antibody from the carrier cell, which is conveniently a hybridoma. Additionally, diagnostic, prophylactic and therapeutic compositions and methods employing the antibody are disclosed. Moreover, a laboratory reagent containing the antibody is described.

US Patent:

48659720, Sep 12, 1989

Filed:

Aug 22, 1986

Appl. No.:

6/899011

Inventors:

Kenneth W. Hunter - Potomac MD

Assignee:

Westinghouse Electric Corp. - Pittsburgh PA

International Classification:

G01N 5300
C12Q 102

US Classification:

435 7

Abstract:

An antibody-based bioassay for enzyme-inducing chemicals is disclosed. The percent induction of an enzyme or class of related enzymes in living cells by an enzyme-inducing chemical in a sample is determined before and after the addition to the sample of an antibody to the chemical. The concentration of the chemical before and after the addition of the antibody is determined by comparison to the percent induction by known concentrations of the chemical. This permits the determination of the concentration of the chemical in the sample.

US Patent:

51146746, May 19, 1992

Filed:

May 1, 1987

Appl. No.:

7/044767

Inventors:

William D. Stanbro - Columbia MD
Kenneth W. Hunter - Potomac MD
Arnold L. Newman - Kensington MD

Assignee:

Biotronic Systems Corporation - Rockville MD

International Classification:

G01N 2702
G01N 33345

US Classification:

422 57

Abstract:

An array of molecular chains is added to a dielectric material between two electrodes of a capacitive affinity sensor. Such an array of molecular chains greatly changes dielectric properties between the two electrodes to greatly enhance sensitivity of the sensor. In a sensor using direct binding, a viral fragment is bound to the sensor's surface. A molecular chain, comprising an anti-viral antibody, an anti-human antibody, and a protein molecule, binds to the viral fragment. In a sensor using competitive binding a hapten is bound to the sensor's surface. A molecular chain, comprising an antibody with attached aliphatic hydrocarbons, binds to the hapten. A free analyte competes with the hapten to bind with the antibody.

US Patent:

49544497, Sep 4, 1990

Filed:

Feb 12, 1988

Appl. No.:

7/155437

Inventors:

Kenneth W. Hunter - Kensington MD
Gerald W. Fischer - Gaithersburg MD

Assignee:

The United States of America as represented by the Secretary of the Army - Washington DC

International Classification:

C12N 500
C07K 1500
C07K 1528

US Classification:

43524027

Abstract:

A human monoclonal antibody produced by a self-reproducing carrier cell, antibody being reactive with PRP capsular polysaccharide. Also disclosed is a process of preparing the antibody from the carrier cell, which is conveniently a hybridoma. Additionally, diagnostic, prophylactic and therapeutic compositions and methods employing the antibody are disclosed. Moreover, a laboratory reagent containing the antibody is described.